Skip to main content
Top
Published in: Clinical Rheumatology 12/2021

01-12-2021 | Shingles | Original Article

Incidence, mortality, and national costs of hospital admissions for potentially preventable infections in patients with rheumatoid arthritis

Authors: Joanna Potera, Soumyasri Kambhatla, Estefania Gauto-Mariotti, Augustine Manadan

Published in: Clinical Rheumatology | Issue 12/2021

Login to get access

Abstract

Introduction

Rheumatoid arthritis (RA) patients have high infection rates. Streptococcus pneumoniae, herpes zoster (HZV), and influenza are common and potentially preventable causes of morbidity and mortality. Vaccinations have been shown to reduce the rates of these infections. In this study, we aim to determine incidence, mortality, and national costs of hospital admissions for Streptococcus pneumoniae, HZV, and influenza infections in patients with RA.

Methods

We conducted a retrospective analysis of the adult RA hospitalizations in 2016 from the National Inpatient Sample database. We limited the RA cases to hospitalizations with a principal discharge diagnosis of S. pneumoniae, HZV, and influenza infections. The total number of discharges, age, length of stay, mortality, and hospital charges were recorded.

Results

In 2016, 552,230 adult hospitalizations had either a primary or secondary diagnosis of RA. Among this group, there were 1120 hospitalizations for influenza, 590 hospitalizations for herpes zoster, and 785 hospitalizations for S. pneumoniae. These infections constituted 0.5% of RA hospitalizations and were a more common cause of hospitalizations when compared to non-RA hospitalizations. Aggregate annual national hospital charges reached $124 million and an aggregate annual LOS of 13,750 days.

Conclusion

Infections, such as influenza, HZV, and S. pneumoniae, remain a common cause of inpatient morbidity and mortality among RA patients. Additionally, the economic burden of these infections is significant. Universal vaccination programs in RA patients, as well as other interventions aiming to improve quality of care of this susceptible population, should be further studied to reduce hospitalizations, cost, morbidity, and mortality.
Key Points
Streptococcus pneumoniae, herpes zoster, and influenza infections remain an important preventable cause of hospitalizations among RA patients and carry significant economic burden.
Literature
6.
go back to reference Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA (2008 Mar) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35(3):387–393PubMed Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA (2008 Mar) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35(3):387–393PubMed
12.
go back to reference Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, Kawabata T, Riese R (2014) Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum 66(10):2675–2684CrossRef Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, Kawabata T, Riese R (2014) Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum 66(10):2675–2684CrossRef
13.
go back to reference Curtis JR, Xie F, Yang S, Bernatsky S, Chen L, Yun H, Winthrop K (2019) Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids. Arthritis Care Res 71(9):1249–1254. https://doi.org/10.1002/acr.23769CrossRef Curtis JR, Xie F, Yang S, Bernatsky S, Chen L, Yun H, Winthrop K (2019) Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids. Arthritis Care Res 71(9):1249–1254. https://​doi.​org/​10.​1002/​acr.​23769CrossRef
18.
go back to reference Doran MF, Gabriel SE (2001) Infections in rheumatoid arthritis - a new phenomenon? J Rheumatol 28(9):1942–1943PubMed Doran MF, Gabriel SE (2001) Infections in rheumatoid arthritis - a new phenomenon? J Rheumatol 28(9):1942–1943PubMed
22.
go back to reference Flood DA, Chan CK, Pruzanski W (1991) Pneumocystis carinii pneumonia associated with methotrexate therapy in rheumatoid arthritis. J Rheumatol 18(8):1254–1256PubMed Flood DA, Chan CK, Pruzanski W (1991) Pneumocystis carinii pneumonia associated with methotrexate therapy in rheumatoid arthritis. J Rheumatol 18(8):1254–1256PubMed
24.
28.
go back to reference Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, Breedveld FC, D ' Amelio R, Dougados M, Kapetanovic MC, van Laar JM, de Thurah A, Landewé RBM, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39–52. https://doi.org/10.1136/annrheumdis-2019-215882CrossRefPubMed Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, Breedveld FC, D ' Amelio R, Dougados M, Kapetanovic MC, van Laar JM, de Thurah A, Landewé RBM, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39–52. https://​doi.​org/​10.​1136/​annrheumdis-2019-215882CrossRefPubMed
29.
go back to reference Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O ' Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St.Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 68(1):1–26. https://doi.org/10.1002/art.39480CrossRef Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O ' Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St.Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 68(1):1–26. https://​doi.​org/​10.​1002/​art.​39480CrossRef
Metadata
Title
Incidence, mortality, and national costs of hospital admissions for potentially preventable infections in patients with rheumatoid arthritis
Authors
Joanna Potera
Soumyasri Kambhatla
Estefania Gauto-Mariotti
Augustine Manadan
Publication date
01-12-2021
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 12/2021
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-021-05836-y

Other articles of this Issue 12/2021

Clinical Rheumatology 12/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.